Allogene Therapeutics
Amy Kinsey currently serves as Vice President of Clinical Operations at Allogene Therapeutics since April 2023. Prior to this role, Amy held the position of Senior Director of Clinical Operations at Atara Biotherapeutics from January 2019 to April 2023, leading clinical operations for cell therapy programs in oncology. Amy's extensive experience at Amgen, from November 1993 to January 2019, includes serving as Director of Global Clinical Program Management, where oversight of clinical development programs in oncology encompassed both small Phase 1b/2 studies and large global Phase 3 trials involving 800 to 2100 subjects. Amy Kinsey earned a Bachelor of Science in Microbiology from California Polytechnic State University-San Luis Obispo from 1988 to 1993.
This person is not in any teams
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.